A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Phase 1 Recruiting 32 enrolled Genentech, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This open-label study will evaluate the effect on the pharmacokinetics (PK), safety, and tolerability of a single oral dose of inavolisib in participants with moderate or severe hepatic impairment compared with demographically matched healthy participants with normal hepatic function.

Timeline

Start: 2025-08-21
Primary completion: 2026-09-04
Completion: 2026-09-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Inavolisib	Small molecule	—	Oral

Indications

No indication recorded.